RxSight, Inc. (RXST)

Market Cap	1.81B
Revenue (ttm)	128.29M
Net Income (ttm)	-30.69M
Shares Out	40.30M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	2,778.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	291,130
Open	45.08
Previous Close	45.12
Day's Range	43.98 - 45.09
52-Week Range	28.12 - 66.54
Beta	1.19
Analysts	Strong Buy
Price Target	61.63 (+37.54%)
Earnings Date	Nov 7, 2024

About RXST

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treat...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 374
• Stock Exchange: NASDAQ
• Ticker Symbol: RXST
• Website: https://www.rxsight.com

Financial Performance

In 2023, RxSight's revenue was $89.08 million, an increase of 81.77% compared to the previous year's $49.01 million. Losses were -$48.61 million, -27.19% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for RXST stock is "Strong Buy." The 12-month stock price forecast is $61.63, which is an increase of 37.54% from the latest price.

Price Target

$61.63

(37.54% upside)

Analyst Consensus: Strong Buy